secwatch.observer — SEC 8-K summary
======================================

Issuer:     TREACE MEDICAL CONCEPTS, INC. (TMCI)
CIK:        0001630627
Form:       8-K
Filed at:   2023-03-07T23:59:59+00:00
Accession:  0000950170-23-006457
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Treace Medical Q4 rev $49.8M (+49% YoY); FY rev $141.8M (+50%); FY23 guide $187-193M
--------------------------------------------------------------------------------

- Q4 revenue $49.8M (+49% YoY); FY2022 revenue $141.8M (+50% YoY).
- Q4 net loss ($4.4M) or ($0.08)/share; Adjusted EBITDA positive $0.3M (vs loss $4.0M in Q4 2021).
- FY2022 net loss ($42.8M) or ($0.77)/share; Adjusted EBITDA loss ($23.7M).
- Completed follow-on offering raising net proceeds $107.5M; cash & securities $81.3M at year-end.
- FY2023 revenue guidance $187-193M (32-36% growth).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1630627/000095017023006457/0000950170-23-006457-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1630627/000095017023006457/tmci-20230307.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-006457

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer